Skip to content
Screener

Discontinued — last reported Q2 '26

Shares (Diluted) at other companies

Illumina logo
IlluminaILMN
153M-2.5%
Quanterix Corporation logo
Quanterix CorporationQTRX
47.2M+21.3%
Revvity logo
RevvityRVTY
111.6M-5.0%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
61.7M+3.4%
Agilent Technologies logo
Agilent TechnologiesA
283M-0.7%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
48.3M+8.3%

Other financials

Income statement

See full
Revenue$39.0M-1.9%
Gross profit$12.6M-13.9%
Operating income-$44.6M+0.5%
Net income-$44.7M-6.7%
EPS (diluted)-$0.140.0%

Balance sheet

See full
Cash & equivalents$62.6M+10.5%
Total debt$61.8M+17.1%
Total equity-$33.2M-154%
Total assets$751.9M-8.9%

Cash flow

See full
Operating cash flow-$35.6M-21.1%
CapEx$1.6M+183%
Free cash flow-$37.1M-24.1%

Valuation

See full
Market cap$357.46M-5.6%
Enterprise value$356.64M-4.8%
P/S2.2×-0.2×

Profitability

See full
Gross margin36.4%+15.0pp
Operating margin-83.5%-37.4pp
Net margin-82.5%-35.5pp
FCF margin-77.5%-13.2pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio4.9×-2.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001299130-26-000122
(In thousands, except per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Unrealized loss on investments(356)(114)(960)(155)
Comprehensive loss$(45,097)$(42,044)$(53,976)$(468,160)
Net loss per share:
Basic$(0.14)$(0.14)$(0.17)$(1.57)
Diluted$(0.14)$(0.14)$(0.17)$(1.57)
Weighted average shares outstanding used in calculating net loss per share:
Basic310,655300,162308,250298,519
Diluted310,655300,162308,250298,519

Item 1. Financial Statements (unaudited):

FAQ

What is Pacific Biosciences of California's shares (diluted)?
Pacific Biosciences of California (PACB) reported shares (diluted) of 310.7M in Q2 2026.
How has Pacific Biosciences of California's shares (diluted) changed year-over-year?
Pacific Biosciences of California's shares (diluted) increased by 3.5% year-over-year, from 300.2M to 310.7M.
What is the long-term trend for Pacific Biosciences of California's shares (diluted)?
Over 4 years (2021 to 2025), Pacific Biosciences of California's shares (diluted) has grown at a 10.2% compound annual growth rate (CAGR), from 812.6M to 1.2B.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Pacific Biosciences of California's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude